Simultaneous detection of FV Q506 and prothrombin 20210 A variation by allele-specific PCR.
OBJECTIVE
Factor V Leiden is the most important risk factor for hereditary thromboembolism, whereas the mutation in the 3'-untranslated region of the prothrombin gene seems to be only a mild risk factor for thrombotic events. On the other hand the factor V mutation (Arg 506) is frequently coinherited with the prothrombin 3'-untranslated region G20210A variant and there is increasing evidence that the co-segregated prothrombin variant is an additional risk factor for venous thromboembolism, contributing to thrombotic manifestations. A rapid, simple and cost-effective screening method is, therefore, required for the detection of both factor V Leiden and the prothrombin variant A20210G.


METHODS
Eighty-eight patients were enrolled in this study. Forty-four had a previously identified factor V and/or prothrombin mutation, the remaining 44 patients served as negative controls. A multiplex allele specific oligonucleotide PCR was established for the simultaneous detection of the two genetic risk factors for thrombophilia. To test the specificity of the simultaneous ASO PCR approach, the mutated and physiological factor V and prothrombin amplification products were sequenced.


RESULTS
The factor V Leiden mutation and the prothrombin variant were correctly identified in all of 44 patients with known mutations. Furthermore the test was able to detect the mutated factor V and the II variant alone, as well as in the cosegregated pattern. Five patients with a homozygous pattern of factor V Leiden or prothrombin variant were also correctly identified. The sensitivity of the test is therefore 100%. In none of the 44 control cases were false positive results seen.


CONCLUSIONS
The ASO PCR test is a rapid, simple and cost-effective screening test for thrombophilia.
Mitterer
M
M
Department of Hematology and Bone Marrow Transplantation Center, L. Boehlerstrasse Nr. 5, I-39031 Bozen/Bolzano, Italy. mitman@dnet.it mitman@dnet.it
Lanthaler
A J
AJ
Mair
W
W
Giacomuzzi
K
K
Coser
P
P
D020016:Activated Protein C Resistance / Q000235:genetics*; D000483:Alleles; D003362:Cost-Benefit Analysis; D004252:DNA Mutational Analysis / Q000191:economics / Q000379:methods*; D005165:Factor V / Q000032:analysis*; D005820:Genetic Testing / Q000191:economics / Q000379:methods*; D014644:Genetic Variation; D005838:Genotype; D006801:Humans; D007020:Hypoprothrombinemias / Q000235:genetics*; D015345:Oligonucleotide Probes; D017354:Point Mutation; D016133:Polymerase Chain Reaction / Q000191:economics / Q000379:methods*; D011401:Promoter Regions, Genetic / Q000235:genetics*; D011516:Prothrombin / Q000032:analysis* / Q000235:genetics; D012680:Sensitivity and Specificity
D015345:Oligonucleotide Probes; C095381:factor V Leiden; D005165:Factor V; D011516:Prothrombin